Yazar "Aydin, Muruvvet Seda" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?
    (Pergamon-Elsevier Science Ltd, 2025) Katircilar, Yavuz; Sahin, Abdulkadir; Aydin, Muruvvet Seda; Erer, Kerim; Erkurt, Mehmet Ali; Namdaroglu, Sinem; Yilmaz, Seda
    Background and objectives: Factors affecting adequate mobilization and apheresis are critical for a good yield of hematopoietic stem cells (HSCs) in the final product. A female donor, advanced age, smoking, high lactate dehydrogenase levels, high absolute lymphocyte count at baseline were found to be inversely correlated to the number of harvested CD34+ cells. However, the data on whether there is a correlation between blood types A, B, AB, O and the number of harvested CD34+ cells is insufficient. The aim of this study is to investigate the effect of blood types on the stem cell yield in healthy donors. Material and methods: A total of 807 healthy donors from 10 centers in T & uuml;rkiye were included in this retrospective study. Donors were subdivided into four groups as A, B, AB, O by their blood types. These four groups were compared in terms of age, sex, ECOG performance score, smoking status, and the amount of harvested CD34+ stem cells. Results: The median age of the 807 healthy donors included in the study was 35 years (11-70). 256 (31.7 %) donors were female and 551 (68.2 %) donors were male. There were 349 donors in type A blood group, 134 in type B blood group, 53 in type AB blood group and 271 donors in type O blood group. The median amount of CD34+ cells in the total apheresis product was 7.67 x 106 per kg in type O blood group, 7.52 x 106 per kg in type A blood group, 7.2 x 106 per kg in type B blood group, and 7.45 x 106 per kg in type AB blood group. There was no statistically significant difference among the groups (p:0.673). Smoking was lower in the type B blood group with 29.1 % compared to the other groups. However, there was no statistically significant difference in total amount of CD34+ stem cells in the type B blood group who smoked less (p = 0.949). Conclusion: In our study in which we have retrospectively analyzed the effect of donor blood types on the efficiency of HSCs harvested from peripheral blood in healthy donors, no correlation was found between the blood types and the mobilization and amount of harvested CD34+ cells.
  • Küçük Resim Yok
    Öğe
    The role of ruxolitinib in the management of acute GVHD
    (Pergamon-Elsevier Science Ltd, 2025) Namdaroglu, Sinem; Hidayet, Emine; Aydin, Muruvvet Seda; Erkurt, Mehmet Ali; Berber, Ilhami; Cinar, Olgu Erkin; Ozet, Gulsum
    Background and objectives: Following an allogeneic hematopoietic stem cell transplant (allo-HSCT), a primary cause of morbidity and mortality is still steroid-refractory acute graft-versus-host disease (SR-aGVHD). Recently, ruxolitinib, an oral inhibitor of JAK1 and JAK2, was approved for use in individuals suffering from SR-aGVHD. This study aimed to analyze the efficacy and toxicity of ruxolitinib in the real world. Material and methods: In the present study, we investigated the effectiveness and toxicity of ruxolitinib in patients with SR-aGVHD using a multicenter retrospective analysis. We enrolled 23 patients between 2018 and 2024 who received ruxolitinib treatment for SR-aGVHD. Results: The first response was acheived in a median of 28 days (range, 12-150). The overall response rate (ORR) for ruxolitinib therapy was 43.5% (10/23) after one month and 61 % (14/23) after two months, respectively. The median overall survival was 69 months. Reactivation of cytomegalovirus (26.1 %) and grade 3-4 anemia (30.4 %) were the two main side effects of ruxolitinib therapy. Seven patients (30.4 %) passed away following a follow-up of a median of six months (range 1-70). The reasons for death included sepsis (n = 2, 28.6 %), progression of aGVHD (n = 3, 42.8 %), and other reasons. Conclusion: Ruxolitinib has an ORR of 61 % for SR-aGVHD, making it a safe and effective therapy choice in realworld settings.